Glycemic Variability and Diabetes Complications: Does It Matter? Simply Put, There Are Better Glycemic Markers!

There is no argument that improving mean levels of glycemic control as judged by assays for glycated hemoglobin (HbA1c) reduces the risks of microvascular complications and cardiovascular disease events in patients with type 1 and type 2 diabetes. However, observations in some trials have suggested that targeting HbA1c to suggested targets may not always result in improved outcomes for people with long-standing type 2 diabetes. The reasons why the glycemic control strategies that primarily use HbA1c in these studies did not have predicted outcomes are not clear. Thus, controversy remains as to whether there are glycemic metrics beyond HbA1c that can be defined as effective measures that can be used in addition to HbA1c to help in assessing the risk of an individual developing diabetes complications. In this regard, the concept of “glycemic variability” (GV) is one metric that has attracted a lot of attention. GV can be simply defined as the degree to which a patient’s blood glucose level fluctuates between high (peaks) and low (nadir) levels. The best and most precise way to assess GV is also one that is still debated. Thus, while there is universal agreement that HbA1c is the current gold standard for the primary clinical target, there is no consensus as to whether other proposed glycemic metrics hold promise to provide additional clinical data or whether there should be additional targets beyond HbA1c. Therefore, given the current controversy, we provide a Point-Counterpoint debate on this issue. In the preceding point narrative, Dr. Hirsch provides his argument that fluctuations in blood glucose as assessed by GV metrics are deleterious and control of GV should be a primary treatment target. In the counterpoint narrative below, Dr. Bergenstal argues that there are better markers to assess the risk of diabetes than GV and provides his consideration of other concepts. —William T. Cefalu Editor in Chief, Diabetes Care

[1]  L. Kessler,et al.  Glucose Variability , 2016, Journal of diabetes science and technology.

[2]  B. Davis,et al.  Design of FLAT-SUGAR: Randomized Trial of Prandial Insulin Versus Prandial GLP-1 Receptor Agonist Together With Basal Insulin and Metformin for High-Risk Type 2 Diabetes , 2015, Diabetes Care.

[3]  R. Vigersky Escaping the Hemoglobin A1c-Centric World in Evaluating Diabetes Mellitus Interventions , 2015, Journal of diabetes science and technology.

[4]  B. Zinman,et al.  Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. , 2015, JAMA.

[5]  S. Matthaei Assessing the value of the Ambulatory Glucose Profile in clinical practice , 2014 .

[6]  M. Evans,et al.  Consensus recommendations for the use of Ambulatory Glucose Profile in clinical practice , 2014 .

[7]  P. Jhund,et al.  Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.

[8]  J. Upadhyay,et al.  Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.

[9]  Harlan M Krumholz,et al.  National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. , 2014, JAMA internal medicine.

[10]  P. Cryer Glycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia , 2014, Diabetes.

[11]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States, 1990-2010. , 2014, The New England journal of medicine.

[12]  R. Ozaki,et al.  Severe Hypoglycemia Identifies Vulnerable Patients With Type 2 Diabetes at Risk for Premature Death and All-Site Cancer: The Hong Kong Diabetes Registry , 2014, Diabetes Care.

[13]  Desmond E. Williams,et al.  Changes in diabetes-related complications in the United States. , 2014, The New England journal of medicine.

[14]  A. Goto,et al.  Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis , 2013, BMJ.

[15]  E. Simonsick,et al.  Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. , 2013, JAMA internal medicine.

[16]  J. Saaddine,et al.  Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.

[17]  D. Klonoff,et al.  Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). , 2013, Diabetes technology & therapeutics.

[18]  W. D. Willis,et al.  Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survey , 2013, Expert review of pharmacoeconomics & outcomes research.

[19]  Yongming Qu,et al.  Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. , 2012, Diabetes technology & therapeutics.

[20]  P. Cryer Severe Hypoglycemia Predicts Mortality in Diabetes , 2012, Diabetes Care.

[21]  L. Blonde,et al.  Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial. , 2012, The Journal of clinical endocrinology and metabolism.

[22]  L. Monnier,et al.  Glycemic Variability: Can We Bridge the Divide Between Controversies? , 2011, Diabetes Care.

[23]  J. DeVries,et al.  A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction , 2011, Diabetes Care.

[24]  R. Heine,et al.  HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycaemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study , 2010, Diabetologia.

[25]  I. Hirsch,et al.  Beyond hemoglobin A1c--need for additional markers of risk for diabetic microvascular complications. , 2010, JAMA.

[26]  Howard Zisser,et al.  Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. , 2009, Diabetes technology & therapeutics.

[27]  B. Zinman,et al.  Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). , 2009, Archives of internal medicine.

[28]  David Rodbard,et al.  Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control. , 2009, Diabetes technology & therapeutics.

[29]  P. Wilson,et al.  Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial , 2009, Diabetes Care.

[30]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[31]  Robert Cuddihy,et al.  Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. , 2008, Diabetes technology & therapeutics.

[32]  B. Zinman,et al.  Effect of Glycemic Exposure on the Risk of Microvascular Complications in the Diabetes Control and Complications Trial—Revisited , 2008, Diabetes.

[33]  J. DeVries,et al.  Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes , 2007, Diabetologia.

[34]  M. Fisher,et al.  Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) , 2007 .

[35]  Michael Brownlee,et al.  The Effect of Glucose Variability on the Risk of Microvascular Complications in Type 1 Diabetes , 2007, Diabetes Care.

[36]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[37]  C. McDonnell,et al.  A novel approach to continuous glucose analysis utilizing glycemic variation. , 2005, Diabetes technology & therapeutics.

[38]  UK Prospective Diabetes Study Group UK prospective diabetes study (UKPDS) , 2004, Diabetologia.

[39]  P. Cryer,et al.  Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes* , 2002, Diabetologia.

[40]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[41]  Uk-Prospective-Diabetes-Study-Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[42]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[43]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[44]  W. F. Taylor,et al.  Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability , 1970, Diabetes.